CONNEQT Health's June quarter saw record consumer revenue growth and a 70% jump in enterprise subscription ARR, supported by a $5.5 million placement and progress on its FDA regulatory pathway for its cloud-based vascular analytics platform.
- Consumer revenue hits record $1.3 million in Q4
- Enterprise clinical subscription ARR grows 70% quarter-on-quarter
- FDA Pre-Submission lodged for SphygmoCloud software platform
- $5.5 million capital raise completed to fund expansion
- Digital subscriptions and in-app purchases accelerate
Consumer Business Drives Record Quarterly Revenue
CONNEQT Health (ASX:CQT) ended FY26 with a strong commercial performance, as its consumer segment hit a quarterly revenue record of $1.3 million, up 21% from the prior quarter. Pulse unit sales surged 33% to 3,574 devices, expanding the installed base that underpins the company’s growing digital health ecosystem.
Digital subscriptions and in-app purchases grew 71% quarter-on-quarter to $68,000, lifting recurring digital revenue to 5% of consumer cash receipts. This early traction validates CONNEQT’s strategy to pivot beyond hardware sales towards higher-margin software monetisation, with premium digital customers generating an estimated lifetime value of $168 per purchaser.
Brand recognition also strengthened, with the CONNEQT Pulse named Best Advanced Blood Pressure Monitor of 2026 by the National Council on Aging, reinforcing its clinical credibility in a competitive consumer health market.
Enterprise Subscriptions Expand Recurring Revenue Base
The enterprise business continued its transition from one-off equipment sales to a subscription-first model, with clinical subscription annual recurring revenue (ARR) climbing 70% to $94,200. Seven new clinical subscription agreements added $38,800 in ARR and $64,500 in total contract value, bringing the cumulative contracted value to $163,800.
CONNEQT is targeting advanced testing centres, concierge medicine, longevity clinics, and performance health providers where arterial health assessment fits naturally into preventive care workflows. The company is also focusing on multi-location preventive health networks to leverage reference-led expansion and improve sales efficiency.
This subscription model reduces adoption friction by lowering upfront costs for healthcare providers and aligns CONNEQT’s revenue with customer utilisation, creating a more predictable and scalable enterprise business.
Advancing Software Platform and Regulatory Pathway
CONNEQT lodged an FDA Pre-Submission for SphygmoCloud, its cloud-based vascular biomarker analytics platform, marking a key milestone in shifting from hardware to software-enabled cardiovascular intelligence. This early regulatory engagement aims to clarify submission requirements and reduce uncertainty, paving the way for future software licensing and enterprise integrations.
Development also progressed on the CONNEQT Pulse Software Development Kit (SDK), designed to integrate Pulse measurements into enterprise clinical workflows and electronic health records, reducing implementation complexity. Meanwhile, the upcoming CONNEQT App Version 2 promises enhanced cardiovascular insights and premium digital services to boost customer engagement and subscription uptake.
Capital Raise Supports Growth and Cash Position
To fund its commercial expansion, CONNEQT completed a $5.5 million institutional placement at $0.022 per share, backed by existing and new sophisticated investors. A Share Purchase Plan targeting $0.5 million remains open until 24 July 2026, offering shareholders a chance to participate on the same terms.
The company ended the quarter with $2.57 million in cash, boosted by convertible debt securities and a new $1.1 million R&D loan facility secured against its FY26 R&D tax incentive refund. Operating cash outflows were $2.47 million for the quarter, reflecting investments in inventory and marketing to support Pulse demand.
Management highlighted over $0.85 million in contracted research and clinical trial receivables expected in Q1 FY27, underpinning near-term cash inflows. Despite a cash runway of just over one quarter at current burn rates, the company expects sustained cash flow improvements from growing revenues and has demonstrated the ability to raise capital when needed.
Research and Pharma Partnerships Bolster Platform Strategy
CONNEQT’s pharmaceutical and research activities contributed approximately $0.8 million in the quarter, supporting diversified revenue and reinforcing its scientific credibility. The company is executing a U.S. Phase 2b pharmaceutical clinical trial that showcases its turnkey vascular assessment services across multiple sites.
Amid challenging academic research funding, CONNEQT is prioritising commercially funded pharmaceutical-sponsored studies and contract research organisation partnerships. It has also centralised its global distribution model to enhance coordination and reactivate international channels, aiming to leverage existing relationships with minimal overhead.
This research foundation is integral to CONNEQT’s long-term vision of a clinically validated cardiovascular intelligence platform spanning consumer, enterprise, pharma, and software channels.
Bottom Line?
CONNEQT’s diversified growth across consumer hardware, enterprise subscriptions, and software platforms positions it well for FY27, but sustaining momentum will require successful execution of its FDA pathway and capital raising initiatives.
Questions in the middle?
- How quickly can CONNEQT convert its FDA Pre-Submission feedback into formal clearance for SphygmoCloud?
- Will digital subscription revenues scale sufficiently to materially uplift overall profitability?
- Can the enterprise subscription model expand beyond niche preventive health providers into broader clinical markets?